Rhenman & Partners Asset Management Ab Rigel Pharmaceuticals Inc Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.12 - $1.82 $1.01 Million - $1.64 Million	-903,761 Reduced 78.07%	253,832 $327,000
Q1 2023 May 11, 2023	SELL	$1.25 - $2.0 $84,360 - $134,976	-67,488 Reduced 5.51%	1,157,593 $1.53 Million
Q2 2022 Aug 12, 2022	SELL	$0.67 - $3.19 $35,301 - $168,077	-52,689 Reduced 4.12%	1,225,081 $1.38 Million
Q1 2022 May 13, 2022	SELL	$2.22 - $3.45 $537,750 - $835,693	-242,230 Reduced 15.94%	1,277,770 $3.82 Million
Q1 2021 May 14, 2021	SELL	$3.35 - $4.93 $724,189 - $1.07 Million	-216,176 Reduced 12.45%	1,520,000 $5.2 Million
Q1 2020 Apr 16, 2020	SELL	$1.27 - $3.0 $208,056 - $491,472	-163,824 Reduced 8.62%	1,736,176 $2.71 Million
Q4 2019 Jan 17, 2020	SELL	$1.6 - $2.43 $160,000 - $243,000	-100,000 Reduced 5.0%	1,900,000 $4.07 Million
Q3 2019 Oct 16, 2019	SELL	$1.63 - $2.62 $431,855 - $694,148	-264,942 Reduced 11.7%	2,000,000 $3.74 Million
Q4 2018 Feb 05, 2019	BUY	$2.08 - $3.36 $313,984 - $507,205	150,954 Added 7.14%	2,264,942 $5.21 Million
Q3 2018 Oct 03, 2018	BUY	$2.6 - $3.59 $1.07 Million - $1.47 Million	410,710 Added 24.11%	2,113,988 $6.79 Million
Q2 2018 Jul 20, 2018	BUY	$2.83 - $4.11 $241,990 - $351,441	85,509 Added 5.29%	1,703,278 $4.82 Million
Q1 2018 Apr 11, 2018	SELL	$3.54 - $4.54 $1.12 Million - $1.43 Million	-315,062 Reduced 16.3%	1,617,769 $5.73 Million
Q4 2017 Jan 19, 2018	SELL	$3.23 - $4.3 $1.35 Million - $1.79 Million	-417,169 Reduced 17.75%	1,932,831 $7.5 Million
Q3 2017 Oct 13, 2017	BUY	$2.18 - $2.57 $5.12 Million - $6.04 Million	2,350,000	2,350,000 $5.97 Million

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account